Search Results
9 results found-
CSL Behring has therapies for treating Factor X Deficiency.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/factor-x-deficiency -
CSL Behring has therapies for treating Fibrinogen Deficiency, a rare bleeding disorder.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/fibrinogen-deficiency -
Factor XIII deficiency affects the ability to stabilize blood clots. Learn more about Factor XIII deficiency, its symptoms and other informational resources.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/factor-xiii-deficiency -
Hemophilia A is an inherited bleeding disorder that involves a deficiency of clotting factor 8. Learn more about hemophilia A symptoms, treatment, and more.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/hemophilia-a -
CSL Behring has therapies for treating von Willebrand Disease (VWD), a typically inherited disease caused by deficient von Willebrand Factor (VWF).
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/von-willebrand-disease -
CSL Behring has therapies for treating Hemophilia B, a bleeding disorder which occurs when a person does not have enough clotting factor IX.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/hereditary-bleeding-disorders/hemophilia-b -
Patients should inform their doctor if they are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.
https://newsroom.csl.com/2025-02-13-European-Commission-Approves-CSLs-ANDEMBRY-R-garadacimab-for-the-Prevention-of-Recurrent-Attacks-of-Hereditary-Angioedema-HAE -
CSL's Board requires that our codes and policies are adhered to by all relevant parties and are reviewed and updated on a regular basis.
https://www.csl.com/we-are-csl/corporate-governance/core-policies -
Equity and Reserves (a) Contributed Equity 2024 2023 US$m US$m Ordinary shares issued and fully paid 5,062 5,022 Share buy-back reserve (4,505) (4,505) Total contributed equity 557 517
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf